| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The National Institutes of Health and The Jackson Laboratory and St. Joseph Hospital, Bangor, Maine 04401
The insulin-like growth factor system (IGF) has been linked to the process of bone acquisition through epidemiologic analyses of large cohorts and in vitro studies of bone cells. But the exact relationship between expression of IGF-I in bone and skeletal homeostasis or pathologic conditions, such as osteoporosis, remains poorly defined. Recent advances in genomic engineering have resulted in the development of better in vivo models to test the role of IGF-I during development and maintenance of the adult skeleton. It is now established that skeletal expression of IGF-I is critical for differentiative bone cell function. It may also be essential for the full anabolic effects of parathyroid hormone on trabecular bone and for some component of biomineralization. Evidence from conditional mutagenesis studies suggests that serum IGF-I may represent more than a storage depot or permissive factor during the final phase of skeletal acquisition. This work re-examines the original tenets of the "somatomedin hypothesis" in light of these newer mouse models and their remarkable skeletal phenotypes. The implications are far reaching and suggest that newer approaches for manipulating the IGF regulatory system may one day be useful as therapeutic adjuncts for the treatment of osteoporosis.
Key Words: IGF-I • periosteum • osteoblasts • bone volume • conditional mutagenesis
This article has been cited by other articles:
|
|
 |
|
  C. J. Xian Roles of Epidermal Growth Factor Family in the Regulation of Postnatal Somatic Growth Endocr. Rev., May 1, 2007; 28(3): 284 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Ali, M. Shim, E. Fowler, M. Greenberg, D. Perkins, W. Oppenheim, and P. Cohen Growth Hormone Therapy Improves Bone Mineral Density in Children with Cerebral Palsy: A Preliminary Pilot Study J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 932 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Bonjour and T. Chevalley Pubertal Timing, Peak Bone Mass and Fragility Fracture Risk IBMS BoneKEy, February 1, 2007; 4(2): 30 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Moerth, M. R. Schneider, I. Renner-Mueller, A. Blutke, M. W. Elmlinger, R. G. Erben, C. Camacho-Hubner, A. Hoeflich, and E. Wolf Postnatally Elevated Levels of Insulin-Like Growth Factor (IGF)-II Fail to Rescue the Dwarfism of IGF-I-Deficient Mice except Kidney Weight Endocrinology, January 1, 2007; 148(1): 441 - 451. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Ueland, S L Fougner, K Godang, T Schreiner, and J Bollerslev Serum GH and IGF-I are significant determinants of bone turnover but not bone mineral density in active acromegaly: a prospective study of more than 70 consecutive patients. Eur. J. Endocrinol., November 1, 2006; 155(5): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Rosen Insulin-Like Growth Factor I and Calcium Balance: Evolving Concepts of an Evolutionary Process Endocrinology, November 1, 2003; 144(11): 4679 - 4681. [Full Text] [PDF]
|
|
|
|
|
|
A. Grey, Q. Chen, X. Xu, K. Callon, and J. Cornish Parallel Phosphatidylinositol-3 Kinase and p42/44 Mitogen-Activated Protein Kinase Signaling Pathways Subserve the Mitogenic and Antiapoptotic Actions of Insulin-Like Growth Factor I in Osteoblastic Cells Endocrinology, November 1, 2003; 144(11): 4886 - 4893. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
